Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of CBP-1008 in Advanced Solid Tumors
NCT04740398Phase 1Recruiting
- Sponsor
- Coherent Biopharma
- Start
- Mar 2019
- Primary completion
- Sep 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ricorfotide vedotin in solid tumor (advanced stage), ovarian cancer, fallopian tube cancer (PFTC) and 9 more, sponsored by Coherent Biopharma. Primary endpoints: Incidence and severity of Adverse Events (AEs) at 12 months and Maximum Tolerated Dose at 28 days. Started Mar 2019; status: recruiting.
02
Drugs
ricorfotide vedotin
03
Conditions
solid tumor (advanced stage)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04740398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04740398.